Phenovista Appoints Pharmaceutical Industry Veteran and Toxicology Expert Eckhard von Keutz, PhD to its Scientific Advisory Board

SAN DIEGO--(BUSINESS WIRE)--Phenovista, a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, today announced the appointment of Eckhard von Keutz to its Scientific Advisory Board. Most recently, Dr. von Keutz served as the Senior Vice President and Head of Translational Science (Preclinical and Early Clinical Development) at Bayer Pharmaceuticals.

“We are excited to welcome Eckhard to our Scientific Advisory Board,” said James Evans, PhD, Chief Executive Officer of Phenovista. “His guidance will be invaluable as continue to deliver high-quality data and unprecedented biological insights to our biopharmaceutical clients, enabling them to more confidently answer complex discovery and development questions and make more informed decisions about development candidates.”

Dr. von Keutz has extensive experience in designing and conducting preclinical/toxicological studies, and toxicological risk assessment and management. In addition to serving as Senior Vice President and Head of Translational Science, his past roles at Bayer included Senior Vice President and Global Head of Early Development, Vice President and Global Head of Healthcare Toxicology, Senior Director and Global Head of Toxicology-Pharma, and Scientific Coordinator of the company’s Toxicology Institute.

“Phenovista’s ability to support and de-risk mission-critical R&D decision-making is unmatched in the industry,” said Dr. von Keutz. “There are significant advantages delivered by their high-plex phenotypic assays as compared to conventional, low-plex in vitro assays throughout the R&D workflow. These advantages are particularly important in toxicological risk assessment as these models have the potential to provide data with increased predictive value and offset the use of in vivo approaches by the biopharmaceutical industry.”

Phenovista develops and offers off-the-shelf and custom phenotypic assays to support a range of R&D activities including toxicology. Toxicological assays include those to assess mitochondrial health, cell viability and cell proliferation. Cell painting assay services in the areas of liver and cardiotoxicity are also available and provide detailed information for compound profiling.

About Phenovista

Founded in 2014, Phenovista is a leader in the development and implementation of multiplexed, high content imaging-based phenotypic assays for biopharmaceutical clients. These assays deliver the high-quality, quantitative data needed to inform and de-risk critical R&D decisions with greater confidence. Clients gain access to novel insights related to the complex biology underlying target validation, therapeutic delivery, efficacy and safety, cytotoxicity, and mechanisms of action, increasing the likelihood of success of first-in-class drug candidates. To learn more, visit our website www.phenovista.com or see us on LinkedIn.

Media Relations:
Christine Quern
cq@christinequern.com
617-650-8497